Literature DB >> 17245724

Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.

Bénédicte Roquebert1, Marc Wirden, Anne Simon, Jérome Deval, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin.   

Abstract

Recent studies have highlighted the need of investigating the in vivo role of ribonuclease H (RNase H) in nucleoside reverse transcriptase inhibitors (NRTIs) resistance. The prevalence of RNase H mutations in naive and in NRTI pre-treated patients in regimen failure were compared and some specific associations between NRTI resistance mutations and RNase H mutations were determined. Four positions were mutated more frequently in pre-treated patients than in naive patients: L469T/I/M/H, T470P/S/E/K, A554T/L/K, and K558R/G/E. Mutations at position K558 were also associated with the number of thymidine analog mutations (TAMs). These results suggest that these mutations could play a role in NRTI resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245724     DOI: 10.1002/jmv.20788

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

Authors:  Atsuko Hachiya; Kazuki Shimane; Stefan G Sarafianos; Eiichi N Kodama; Yasuko Sakagami; Fujie Negishi; Hirokazu Koizumi; Hiroyuki Gatanaga; Masao Matsuoka; Masafumi Takiguchi; Shinichi Oka
Journal:  Antiviral Res       Date:  2009-02-21       Impact factor: 5.970

Review 2.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

3.  Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.

Authors:  Jessica H Brehm; Christina M Lalama; Michael D Hughes; Richard Haubrich; Sharon A Riddler; Nicolas Sluis-Cremer; John W Mellors
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

4.  Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

Authors:  Jessica H Brehm; Dianna L Koontz; Carole L Wallis; Kathleen A Shutt; Ian Sanne; Robin Wood; James A McIntyre; Wendy S Stevens; Nicolas Sluis-Cremer; John W Mellors
Journal:  Clin Infect Dis       Date:  2012-05-22       Impact factor: 9.079

5.  Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.

Authors:  Paula Ordonez; Takayuki Hamasaki; Yohei Isono; Norikazu Sakakibara; Masahiro Ikejiri; Tokumi Maruyama; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

6.  Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Authors:  Soumi Gupta; Signe Fransen; Ellen E Paxinos; Eric Stawiski; Wei Huang; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

7.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

8.  Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.

Authors:  Michel Ntemgwa; Mark A Wainberg; Maureen Oliveira; Daniela Moisi; Richard Lalonde; Valeria Micheli; Bluma G Brenner
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

9.  Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance.

Authors:  Jessica H Brehm; John W Mellors; Nicolas Sluis-Cremer
Journal:  Biochemistry       Date:  2008-12-30       Impact factor: 3.162

10.  Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.

Authors:  Jessica H Brehm; Dianna Koontz; Jeffrey D Meteer; Vinay Pathak; Nicolas Sluis-Cremer; John W Mellors
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.